Clinical trial
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
NCT00451321 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00451321 |
|---|---|
| Title | TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM) |
| Official title | TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD) |
| Acronym | TTEDD |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Juvenile Diabetes Research Foundation |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Otelixizumab |
| Enrollment | 88 |
| Start date | Jul 31, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Mar 23, 2007 |
| Last update posted | Nov 13, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: